Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04882449 · ClinicalTrials.gov registry record
Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events
A clinical trial, sponsored by Bodyport.
- Completed
- Registry status
- 329
- Enrollment target
NCT04882449: Completed study, sponsored by Bodyport.
NCT04882449 is a clinical trial that has completed, run by Bodyport. The registered enrollment target is 329 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04882449 has completed, sponsored by Bodyport.
- COMPLETED
- Registry status
- 329 participants
- Enrollment target
Study Summary
The main goal of this study is to use data from the Bodyport Cardiac Scale to help detect of worsening heart failure (HF) early.
Primary Outcome
Worsening HF will be defined as a composite of the following: urgent, unscheduled clinic or emergency department visit or hospital admission with a primary diagnosis of HF in which the patient exhibited new or worsening symptoms of HF on presentation, had objective evidence of new or worsening HF, and received initiation or intensification of treatment for HF.
Interventions
- DEVICE Bodyport Cardiac Scale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2021-07-08 |
| Est. Completion | 2023-07-31 |
What the finished NCT04882449 record still lists
NCT04882449 is an observational study that tracks outcomes without assigning an intervention. The registered 329 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Bodyport Cardiac Scale is the first listed.
NCT04882449 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04882449 about?
NCT04882449 is a clinical study titled "Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events". The main goal of this study is to use data from the Bodyport Cardiac Scale to help detect of worsening heart failure (HF) early.
What is the current status of trial NCT04882449?
This trial is currently completed. The enrollment target is 329 participants. The study started on 2021-07-08. Estimated completion is 2023-07-31.
What interventions are being tested in trial NCT04882449?
The interventions under investigation include: Bodyport Cardiac Scale (DEVICE).
Who is sponsoring clinical trial NCT04882449?
This trial is sponsored by Bodyport, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06036446 · 329 participants · NA
LATe Cerclage in High-risk Pregnancies (LATCH)
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI